Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II, 24-week Study Investigating the Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy Refractory to Oral NSAIDs/Acetaminophen, Physiotherapy or Corticosteroid Injections
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Musculoskeletal disorders; Pain; Tendinitis
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 05 Jun 2021 Results assessing efficacy and safety of Secukinumab in patients with rotator cuff tendinopathy presented at the 22nd Annual Congress of the European League Against Rheumatism
- 09 Dec 2019 Status changed from active, no longer recruiting to completed.
- 01 Sep 2019 the trial has been Discontinued in Netherlands according to European Clinical Trials Database